International Myeloma Working Group recommendations for global myeloma care (Q38157532)

29 August 2017

title

International Myeloma Working Group recommendations for global myeloma care (English)

1 reference

29 August 2017

5

1 reference

29 August 2017

R Hajek

12

0 references

Athanasios Dimopoulos

3

object named as

M A Dimopoulos

1 reference

29 August 2017

21

B Durie

1 reference

29 August 2017

10

A Jurczyszyn

1 reference

29 August 2017

H Ludwig

1

1 reference

29 August 2017

J S Miguel

2

1 reference

29 August 2017

A Palumbo

4

1 reference

29 August 2017

R Powles

6

1 reference

29 August 2017

S Lentzsch

7

1 reference

29 August 2017

W Ming Chen

8

1 reference

29 August 2017

J Hou

9

1 reference

29 August 2017

K Romeril

11

1 reference

29 August 2017

E Terpos

13

1 reference

29 August 2017

K Shimizu

14

1 reference

29 August 2017

D Joshua

15

1 reference

29 August 2017

V Hungria

16

1 reference

29 August 2017

A Rodriguez Morales

17

1 reference

29 August 2017

D Ben-Yehuda

18

1 reference

29 August 2017

P Sondergeld

19

1 reference

29 August 2017

E Zamagni

20

1 reference

29 August 2017

publication date

9 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

28

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

981-992

1 reference

The genetic architecture of multiple myeloma.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

New strategies in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Have drug combinations supplanted stem cell transplantation in myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

IMWG consensus on maintenance therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

European perspective on multiple myeloma treatment strategies: update following recent congresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Supportive care in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Management of complications in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Pathogenesis and treatment of renal failure in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Management of anemia in cancer patients: transfusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Thrombosis is associated with inferior survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Thrombosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Evidence-based standards for cancer pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.293

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

21 January 2018

1 reference

12 December 2020

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

1 reference

12 December 2020

Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry

1 reference

12 December 2020

Multiple myeloma: review of 869 cases

1 reference

12 December 2020

Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma

1 reference

12 December 2020

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

12 December 2020

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

1 reference

12 December 2020

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

12 December 2020

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

1 reference

12 December 2020

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

1 reference

12 December 2020

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

12 December 2020

Bisphosphonates in multiple myeloma: a network meta-analysis

1 reference

12 December 2020

Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival

1 reference

12 December 2020

Primary dexamethasone treatment of multiple myeloma

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.293

1 reference

Dimensions Publication ID

29 August 2017

1013434190

0 references

1 reference